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 Macular pigment levels increase following blue-light filtering  
intraocular lens implantation 
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1Macular Pigment Research Group, Department of Chemical & Life Sciences, Waterford Institute of Technology, Waterford, Ireland;  
2Macular Pigment Research Group, Optometry Department, Dublin Institute of Technology, Dublin, Ireland 
INTRODUCTION 
Age-related macular degeneration (AMD), which damages central vision, is 
the most common cause of age-related blindness in the western world.  
There is a growing body of evidence suggesting that oxidative stress is 
important in the pathogenesis of this condition and that cumulative short-
wavelength (blue) light damage plays a role.  Macular pigment (MP), 
consisting of the carotenoids: lutein (L), zeaxanthin (Z) and meso-Z, has a 
maximum absorption at 460nm and protects the retina from (photo)-oxidative 
injury.  
 
Alcon have been producing a yellow (blue-light filtering) IOL, the Alcon 
AcrySof Natural SN60AT® (ANIOL) since the year 2000.  The ANIOL is 
similar to the standard, and commonly used, AcrySof SA60AT single-piece 
acrylic IOL (AIOL); however, it has a blue-light filtering capacity.  The ANIOL 
was one of the first foldable IOLs to imitate the transmittance of the natural 
crystalline lens by combining a UV blocker with a covalently bound 
chromophore that partly absorbs light in the 400 to 500 nm spectral range.   
  
PURPOSE 
This study was designed to investigate whether the blue-light filtering 
properties of the ANIOL implanted during cataract surgery impacts on MP 
optical density (MPOD). 
 
SUBJECTS and METHODS 
Forty two patients scheduled for cataract surgery were recruited into the 
study. These patients all had pre-operative best corrected visual acuity rating 
(BCVAR) of at least 0.5 (logMAR) in the study eye.  Patients were 
randomised to have either the standard AIOL (controls) or the ANIOL 
implanted at the time of cataract surgery. The spatial profile of MPOD (i.e. at 
0.25o, 0.5o, 1o  and 1.75o eccentricity) was measured with the Macular 
Densitometer™ using customised heterochromatic flicker photometry (cHFP) 
one week pre-operatively and one-week post-operatively, and at three, six 
and 12 months following surgery [Fig. 1].  Serum concentrations of L and Z 
were also measured by high-performance liquid chromatography (HPLC) at 
each study visit [Fig. 2].  
    
        
        
        
      
        
      
      
    
      
    
    
      
      
      
      
  
RESULTS 
Of the 42 patients recruited into the trial, 30 attended all study visits (1 week pre-
surgery, 1 week post-surgery, three-month visit, six-month visit, and 12-month visit 
[V1, V2, V3, V4, and V5, respectively).  One patient from the AIOL group dropped 
out after V1, two after V2, and two after V4 (n = 5 drop-outs in total).  Three 
patients from the ANIOL group dropped out after V1, two after V2, and two after 
V4 (n = 7 drop-outs in total).  Reasons for drop-out were as follows: patient illness 
(non-ocular pathology); patient deceased; logistics of transport; not interested in 
participating further.  
 
Macular Pigment Optical Density 
We conducted a repeated measures analysis of average MPOD across the retina, 
measured at each of five study visits using a general linear model approach, with 
lens as a between-patients factor.  This resulted in a statistically significant 
time/lens interaction effect, which remained significant (p < 0.05) using any of the 
standard corrections for violation of sphericity.  It is clear from the means plots of 
Fig. 3 and MPOD values presented in Table 1, how this significant time/lens 
interaction effect arises: MPOD increases with time (at least for some patients) in 
the ANIOL group, but remains virtually static in the AIOL group. 
 
CONCLUSION 
In conclusion, this study provides evidence that implanting an IOL that filters 
blue light (ANIOL) results in augmentation of MPOD. The importance of this 
finding rests on the fact that any benefits associated with augmentation of 
MPOD, in terms of AMD prevention or progression (yet to be proven), will be 
conferred on patients implanted with an ANIOL at the time of cataract surgery, 
and may be of particular importance in the modern era where IOL implantation 
often occurs at an earlier stage in a patient’s lifetime (such as in paediatric 
cataract surgery, refractive lens exchange and relatively early lens opacity in 
patients with a long post operative life expectancy).  However, further study is 
required in the form of controlled long-term trials to investigate whether 
implantation of a blue-light filtering IOL is effective in preventing or delaying 
AMD development or progression. 
 
 
 
Figure 1. The Macular Densitometer™ 
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Figure 2. Agilent 1200 HPLC series 
AIOL         
Subject V1 V2  V3  V4  V5  V3-V2 V4-V2 V5-V2 
2 0.09 0.07 0.11 0.07 0.07 0.04 0 0 
5 0.4 0.45 0.38 0.43 0.4 -0.07 -0.02 -0.05 
7 0.3 0.17 0.14 0.11 0.12 -0.03 -0.06 -0.05 
11 0.03 0.07 0.06 0.02 0.03 -0.01 -0.05 -0.04 
12 0.05 0.01 0 0.01 0 -0.01 0 -0.01 
14 0.43 0.38 0.38 0.42 0.37 0 0.04 -0.01 
16 0.21 0.27 0.29 0.32 0.26 0.02 0.05 -0.01 
18 0.18 0.13 0.19 0.19 0.25 0.06 0.06 0.12 
21 0.33 0.28 0.3 0.27 0.27 0.02 -0.01 -0.01 
27 0.14 0.13 0.09 0.09 0.11 -0.04 -0.04 -0.02 
29 0.16 0.1 0.07 0.15 0.12 -0.03 0.05 0.02 
32 0.12 0.13 0.12 0.12 0.16 -0.01 -0.01 0.03 
34 0.15 0.13 0.15 0.13 0.12 0.02 0 -0.01 
Mean 0.20 0.18 0.18 0.18 0.18 0.00 0.00 0.00 
SD 0.13 0.13 0.12 0.14 0.12 0.04 0.04 0.04 
 
ANIOL         
Subject V1 V2  V3  V4  V5  V3-V2 V4-V2 V5-V2 
3 0.28 0.29 0.3 0.36 0.39 0.01 0.07 0.1 
6 0.36 0.21 0.32 0.34 0.34 0.11 0.13 0.13 
8 0.09 0.12 0.3 0.43 0.45 0.18 0.31 0.33 
9 0.03 0.02 0.01 0.01 0 -0.01 -0.01 -0.02 
10 0.12 0.1 0.07 0.07 0.06 -0.03 -0.03 -0.04 
17 0.22 0.25 0.28 0.17 0.25 0.03 -0.08 0 
19 0.37 0.43 0.28 0.38 0.52 -0.15 -0.05 0.09 
20 0.04 0.06 0.07 0.15 0.08 0.01 0.09 0.02 
22 0.12 0.17 0.26 0.36 0.47 0.09 0.19 0.3 
26 0.13 0.32 0.44 0.58 0.54 0.12 0.26 0.22 
40 0.17 0.11 0.08 0.08 0.11 -0.03 -0.03 0 
Mean 0.18 0.19 0.22 0.27 0.29 0.03 0.08 0.10 
SD 0.12 0.12 0.14 0.18 0.20 0.09 0.13 0.13 
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Table 1. 
Figure 3. 
Serum Lutein and Zeaxanthin 
There were no significant serum L effects observed over the study period [Fig. 
4].  There was a significant time effect for serum Z over the study period 
(repeated measures, general linear model, e.g. using Huynh-Feldt correction 
for sphericity, p = 0.038), but not a significant time/lens interaction (p > 0.05 for 
all tests) [Fig. 5].  Thus, serum Z was significantly different at different time 
points, but this was true in both the AIOL and ANIOL groups. 
 
 Figure 4. 
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Figure 5. 
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